| Business Summary | | HemaCare
Corporation
collects,
processes
and
distributes
blood
products
to
hospitals
in
the
United
States.
Additionally,
the
Company
provides
blood-related
services
(therapeutic
apheresis
(TA)),
on
a
mobile
basis,
to
patients
with
a
variety
of
disorders.
Therapeutic
apheresis
is
usually
provided
in
the
hospital
setting
under
contractual
arrangements
with
the
hospital
as
an
outside
purchased
service.
The
Company
markets
its
products
and
services
as
HemaCare
Corporation
(HemaCare)
in
California
and
Coral
Blood
Services,
Inc.
(Coral)
in
other
states.
The
Company
essentially
has
three
lines
of
business
or
modes
of
operation,
which
consist
of
regional
blood
product
operations,
regional
therapeutic
services
and
blood
management
programs. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HemaCare
Corp.
provides
blood
component
products,
including
single
donor
apheresis
platelets
and
therapeutic
aspheresis
services
to
hospitals.
For
the
three
months
ended
3/31/01,
revenues
increased
22%
to
$6.1
million.
Net
income
decreased
33%
to
$219
thousand.
Revenues
reflect
the
expansion
of
the
California
based
Blood
Management
Programs.
Net
income
was
offset
by
a
decreased
gross
profit
due
to
lower
levels
of
profitability. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
6,238;
after
tax
earnings
were
153. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Alan Darlington, 50 Chairman | $260K | William Nicely, 53 Pres,
CEO, Director and Chief Exec. Officer, Western U.S Operations | 229K | David Fractor, 41 CFO | 118K | Dana Belisle, 37 COO
and Pres of Coral Blood Services | 123K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|